Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNS 401 NG

Drug Profile

SNS 401 NG

Alternative Names: MPCvV phage - Sensei Biotherapeutics; SNS-401; SNS-401-NG

Latest Information Update: 06 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sensei Biotherapeutics
  • Developer Sensei Biotherapeutics; University of Washington
  • Class Antineoplastics; Bacteriophages; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Merkel cell carcinoma

Most Recent Events

  • 28 Jun 2021 Sensei Biotherapeutics announces intention to submit an IND application to the US FDA for Merkel cell carcinoma in the first half of 2022
  • 28 Jun 2021 Sensei plans a broader basket study for Head and neck cancer, Lung cancer, Malignant melanoma, and triple negative Breast cancer based on the prevalence of Phortress antigens, if clinical proof of concept is achieved
  • 28 Jun 2021 Sensei Biotherapeutics announces intention to initiate IND-enabling studies for Merkel cell carcinoma in USA, in the second half of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top